Cargando…
Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients
BACKGROUND: A cure for the heterogeneous hematological malignancy multiple myeloma (MM) is yet to be developed. To date, the early risk factors associated with poor outcomes in MM have not been fully elucidated. Studies have shown an aberrant complement system in patients with MM, but the precise as...
Autores principales: | Zhang, Lihua, Ling, Xiaosui, Li, Fan, Yang, Tonghua, Shi, Keqian, Zhao, Shixiang, Yu, Liqun, Li, Zengzheng, He, Haiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891941/ https://www.ncbi.nlm.nih.gov/pubmed/35250324 http://dx.doi.org/10.1177/11795549221079171 |
Ejemplares similares
-
Increased Cytokine Levels Assist in the Diagnosis of Respiratory Bacterial Infections or Concurrent Bacteremia in Patients With Non-Hodgkin’s Lymphoma
por: Zhang, Lihua, et al.
Publicado: (2022) -
Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia
por: Zhao, Shixiang, et al.
Publicado: (2023) -
Cytokine Expression of Lung Bacterial Infection in Newly Diagnosed Adult Hematological Malignancies
por: Li, Zengzheng, et al.
Publicado: (2021) -
The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014) -
Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)